Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Gross Profit (2021 - 2025)

Historic Gross Profit for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $114.1 million.

  • BridgeBio Pharma's Gross Profit rose 524850.05% to $114.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.8 million, marking a year-over-year increase of 5732.75%. This contributed to the annual value of $218.0 million for FY2024, which is 307958.29% up from last year.
  • Per BridgeBio Pharma's latest filing, its Gross Profit stood at $114.1 million for Q3 2025, which was up 524850.05% from $106.9 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Gross Profit ranged from a high of $210.5 million in Q1 2024 and a low of -$2.4 million during Q4 2021
  • Moreover, its 5-year median value for Gross Profit was $2.1 million (2024), whereas its average is $37.7 million.
  • Per our database at Business Quant, BridgeBio Pharma's Gross Profit plummeted by 14505.62% in 2022 and then soared by 1781676.6% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Gross Profit (Quarter) stood at -$2.4 million in 2021, then soared by 151.36% to $1.2 million in 2022, then decreased by 6.21% to $1.1 million in 2023, then skyrocketed by 231.12% to $3.8 million in 2024, then soared by 2905.19% to $114.1 million in 2025.
  • Its last three reported values are $114.1 million in Q3 2025, $106.9 million for Q2 2025, and $114.0 million during Q1 2025.